Aselizumab, designated HuDreg-55, signifies a novel monoclonal antibody designed to interact with C1q. How it works utilizes disrupting the initial complement pathway, potentially offering efficacy in https://aselizumab-mab444557.newsyblog.com/103425/aselizumab-a-detailed-exploration-into-hudreg-55